1[1]Huestis MA.Cannabis(Marijuana)-Effects on human behavior and performance[J].Forensic Sci Rev,2002,14(15):17-27.
2[2]Valiveti S,Agu RU,Hammell DC,et al.Intranasal absorption of Delta9-tetrahydrocannabinol and WIN55,212-2 mesylate in rats[J].Eur J Pharm Biopharm,2006,64(3):361-365.
3[3]Grotenhermen F.Pharmacokinetics and pharmacodynamics of cannabinoids[J].Clin Pharmacokinet,2003,42(4):327-360.
4[4]Green KE,Kearse CE.Ocular penetration of topical Delta9-tetrahydrocannabinol from rabbit corneal or cul-de-sac application site[J].Curr Eye Res,2000,21(1):566-570.
5[5]Bland TM,Haining RL,Tracy T,et al.CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism:kinetics,pharmaco-genetics and interaction with phenytoin[J].Biochem Pharmacol,2005,70(7):1096-1103.
6[6]Moore C,Ross W,Coulter C,et al.Detection of the marijuana metabolite 11-nor-Delta9-tetrahydrocannabinol-9-carboxylic acid in oral fluid specimens and its contribution to positive results in screening assays[J].J Anal Toxicol,2006,30(7):413-418.
7[7]Kintz P,Cirimele V,Ludes B.Detection of cannabis in oral fluid (saliva) and forehead wipes (sweat) from impaired drivers[J].J Anal Toxicol,2000,24(7):557-561.
8[8]Lin DL and Lin RL.Distribution of 11-nor-9-carboxy-Delta9 -tetrahydrocannabinol in traffic fatality cases[J].J Anal Toxicol,2005,29(1):58-61.
9[9]Harvey DJ.Absorption,distribution and biotransformation of the cannabinoids[A].Marijuana and Medicine[M].Totowa:Humana Press,2001,91-92.
10[10]Goodwin RS,Gustafson RA,Barnes A,et al.Delta9-tetrahydrocannabinol,11-hydroxy-delta9-tetrahydrocannabin -ol and 11-nor-9-carboxy-delta9-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids[J].Ther Drug Monit,2006,28(4):545-551.
同被引文献7
1沈敏.体内滥用药物分析[M]{H}北京:法律出版社,2003.
2Frens G. Controled nucleation for the regulation of the particle size in monodisperse gold suspensions[J].Nat Phys Sci,1976,(105):20.
